AMPLIFY-7P randomised ph2

Grainne O'Kane· @graokane · X·2026-10-23 21:08· 2 days agoScore90

Body · original

AMPLIFY-7P randomised ph2
✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile
➡️curative intent & no recurrence <6mth #PDAC
✅T cell responses,primary endpt-ve
➡️benefit in ctDNA-ve& no rads?
➡️DFS @6mth benefit of 14% p=0.056
✅ph3 planned
@myESMO @OncoAlert #ESMO26

452 views · 9 likes · 13 reposts · 1 reply

Conference abstracts

LBA82matched by Proffered paper 1: Gastrointestinal tumour, upper digestive

Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study

https://esmocongress.esmo.org

LBA83matched by Proffered paper 1: Gastrointestinal tumour, upper digestive

Seven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma (PDAC): The AMPLIFY-7P randomized phase 2 study

https://esmocongress.esmo.org

Replies in this thread

Santhosh Ambika@RenoHemonc
@graokane @myESMO @OncoAlert Neoantigen based probably better than off the shelf ?

Source: Grainne O'Kane · x.com